eli lilly retatrutide phase 3 trial Medscape | Retatrutide, Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Eli Lilly's Phase 3 clinical
Description
Ongoing monitoring: Expect periodic A1C testing, immediate reporting of dose changes/side effects and re-grounding after each dose adjustment as required
N Engl J Med 2023;389:1069-84
Aukrust, I
Further detail on the European regulatory review carried out is available here.
